Low-dose alemtuzumab for GvHD prevention followed by prophylactic donor lymphocyte infusions in high-risk leukemia.

about

Low-dose alemtuzumab for GvHD prevention followed by prophylactic donor lymphocyte infusions in high-risk leukemia.

Item

http://www.wikidata.org/entity/Q51017254

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Low-dose alemtuzumab for GvHD ...... fusions in high-risk leukemia.

@en

Low-dose alemtuzumab for GvHD ...... fusions in high-risk leukemia.

@nl

type

Item

label

Low-dose alemtuzumab for GvHD ...... fusions in high-risk leukemia.

@en

Low-dose alemtuzumab for GvHD ...... fusions in high-risk leukemia.

@nl

prefLabel

Low-dose alemtuzumab for GvHD ...... fusions in high-risk leukemia.

@en

Low-dose alemtuzumab for GvHD ...... fusions in high-risk leukemia.

@nl

P1476

Low-dose alemtuzumab for GvHD ...... fusions in high-risk leukemia.

@en

P2093

A Sarantopoulos

http://www.w3.org/2001/XMLSchema#string

A Spyridonidis

http://www.w3.org/2001/XMLSchema#string

E Triantafyllou

http://www.w3.org/2001/XMLSchema#string

I Pessach

http://www.w3.org/2001/XMLSchema#string

K Gkirkas

http://www.w3.org/2001/XMLSchema#string

M Liga

http://www.w3.org/2001/XMLSchema#string

M Marangos

http://www.w3.org/2001/XMLSchema#string

M Stamouli

http://www.w3.org/2001/XMLSchema#string

N Spyridis

http://www.w3.org/2001/XMLSchema#string

P2860

Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials.

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.

Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO).

Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study.

Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.

High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.

Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.

Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia

P2888

bmt.2016.272

P304

445-451

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2016.272

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P Tsirigotis

P577

2016-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27941776

http://www.w3.org/2001/XMLSchema#string